RASA3 gene role in pulmonary arterial hypertension
Official title: RASA3 is a Candidate Gene in the Pathogenesis of Pulmonary Arterial Hypertension
Funded at Indiana University Indianapolis · NIH-11396286 · Data updated 2026-11-12
A scientist will study how the RASA3 gene affects cells in pulmonary arteries to understand a severe lung condition called PAH.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | August 22, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $156,416 |
| NIH project number | 5K08HL179459-02 |
| Project ID | NIH-11396286 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with pulmonary arterial hypertension or at risk due to related genetic factors/biomarkers.
✕Less likely to help
The study uses animal models and data; direct benefit to every patient in the near term is not guaranteed.
What this research studies
This project uses a mouse model where RASA3 is deleted in endothelial cells to see how it changes blood vessel behavior related to PAH. It will also examine human data showing RASA3 levels and a genetic variant that may influence disease severity. The goal is to identify how RASA3 controls endothelial cell survival, proliferation, and vessel integrity in PAH. Findings could point to new targets for therapies to help people with PAH live longer and better.
Why it matters
Potential benefit: If successful, the research could reveal new molecular targets to develop treatments for PAH.
How similar studies have gone: Preclinical work suggests RASA3 is linked to endothelial function and PAH, supporting potential translational relevance.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Prohaska, Clare — Indiana University Indianapolis
- Study coordinator: Prohaska, Clare
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.